TMDX Earnings & Financial Statements
TransMedics Group, Inc.
$77.87
-$1.13(-1.43%)
41
Overall
50
Value
10
Tech
65
Quality
Market Cap
$2.70B
Volume
733.74K
52W Range
$60.11 - $156.00
Target Price
$94.82
TMDX earnings and financial statements: TransMedics Group, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
TMDX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $605.49M | $441.54M | $241.62M | $93.46M | $30.26M |
| Cost of revenue | $242.69M | $179.46M | $87.53M | $28.19M | $72.0K |
| Operating income | $108.58M | $37.50M | -$28.73M | -$31.44M | -$39.43M |
| EBITDA | $148.49M | $69.95M | -$7.70M | -$28.58M | -$38.49M |
| Net income | $190.29M | $35.46M | -$25.03M | -$36.23M | -$44.22M |
| EPS (diluted) | $4.87 | $1.07 | $-0.77 | $-1.23 | $-1.60 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.07B | $804.08M | $706.05M | $277.15M | $134.89M |
| Total liabilities | $595.27M | $575.47M | $568.85M | $89.77M | $67.04M |
| Shareholders’ equity | $473.10M | $228.60M | $137.20M | $187.38M | $67.85M |
| Cash and equivalents | $488.40M | $336.65M | $394.81M | $201.18M | $25.58M |
| Long-term debt | $505.97M | $515.56M | $513.91M | $66.11M | $43.80M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $192.84M | $48.80M | -$13.03M | -$45.82M | -$28.86M |
| Capital expenditure | -$59.25M | -$129.74M | -$179.06M | -$11.91M | -$3.52M |
| Free cash flow | $133.59M | -$80.94M | -$164.88M | -$57.72M | -$32.38M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TMDX | $77.87 | -1.4% | 733.74K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |